Guidelines and Precision Medicine in cSCC

This episode, titled “Guidelines and Precision Medicine in cSCC,” features panelists discussing the evolving role of clinical guidelines and molecular profiling in the management of cutaneous squamous cell carcinoma (cSCC). The expert faculty explore how gene expression profiling (GEP) is being integrated into real-world practice and how clinicians balance evidence-based guidelines with individualized patient care and emerging precision medicine approaches.

The panel reviews how current guidelines shape decision-making around molecular profiling while acknowledging that clinical practice and evolving evidence may outpace formal guideline updates. Using comparisons to established molecular testing approaches in other cancers, such as Oncotype DX in breast cancer, the expert faculty discuss how GEP may influence management decisions even before widespread incorporation into consensus recommendations.

Additionally, the discussion examines practical questions surrounding implementation of GEP in clinical practice, including which patients may benefit most from testing and how clinicians interpret and act upon molecular risk classifications. The panelists highlight how GEP results may support decisions regarding radiation therapy, follow-up intensity, imaging, and multidisciplinary management, particularly for patients with high-risk features or tumors that may not be adequately characterized by traditional staging systems alone. The expert faculty also discuss ongoing evidence gaps related to imaging, immunotherapy, and neoadjuvant treatment strategies, while emphasizing the growing role of precision medicine in personalizing treatment selection and improving patient outcomes in cSCC management.

In the next episode, “Personalized Management in cSCC,” panelists will continue discussing future directions in molecular profiling, evolving precision medicine strategies, and practical considerations for integrating emerging diagnostic tools into cSCC management.